Utilizing Autologous Multipotent Mesenchymal Stromal Cells and -Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial.

0459625 - ÚEM 2017 RIV US eng J - Journal Article
Šponer, P. - Filip, S. - Kučera, T. - Brtková, J. - Urban, K. - Palička, V. - Kočí, Zuzana - Syka, Michael - Bezrouk, A. - Syková, Eva
Utilizing Autologous Multipotent Mesenchymal Stromal Cells and -Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial.
BioMed Research International. Roč. 2016, č. 2016 (2016), s. 2076061. ISSN 2314-6133. E-ISSN 2314-6141
R&D Projects: GA MZd(CZ) NT13477; GA MŠMT(CZ) LO1309
Institutional support: RVO:68378041
Keywords : total hip-arthroplasty * stem-cells * in-vivo * transplantation * classification
Subject RIV: FI - Traumatology, Orthopedics
Impact factor: 2.476, year: 2016

The purpose of this prospective controlled study was to compare healing quality following the implantation of ultraporous β-tricalcium phosphate, containing either expanded autologous mesenchymal stromal cells (trial group, 9 patients) or β-tricalcium phosphate alone (control group, 9 patients), into femoral defects during revision total hip arthroplasty. Both groups were assessed using the Harris Hip Score, radiography, and DEXA scanning at 6 weeks and 3, 6, and 12 months postoperatively. A significant difference in the bone defect healing was observed between both groups of patients (P<0.05). In the trial group, trabecular remodeling was found in all nine patients and in the control group, in 1 patient only. Whereas, over the 12-month follow-up period, no significant difference was observed between both groups of patients in terms of the resorption of β-tricalcium phosphate, the significant differences were documented in the presence of radiolucency and bone trabeculation through the defect (P<0.05). Using autologous mesenchymal stromal cells combined with a β-tricalcium phosphate scaffold is a feasible, safe, and effective approach for management of bone defects with compromised microenvironment. The clinical trial was registered at the EU Clinical Trials Register before patient recruitment has begun (EudraCT number 2012-005599-33).
Permanent Link: http://hdl.handle.net/11104/0259807